Gene Therapies Move From Experimental to Available for Rare Diseases
A growing number of approved gene therapies are transforming care for once-untreatable rare conditions, though access and cost remain hurdles.
Gene therapies, long the stuff of scientific promise, are increasingly moving from the experimental realm into approved treatments, transforming care for a growing list of rare diseases that once had few or no options.
These therapies work by addressing the genetic root of a disease rather than merely managing symptoms, and for some conditions they offer the prospect of durable, even one-time, treatment. For patients and families, the arrival of an option can be life-changing.
Real progress
The list of approved therapies has expanded steadily, spanning certain inherited disorders, some blood conditions, and select vision-related diseases. Each approval represents years of research finally reaching the people it was meant to help.
The advances are not without complexity. The treatments are highly specialized, delivered at a limited number of centers, and their long-term durability is still being studied as the first cohorts of patients are followed over time.
Access and cost
The central challenges now are access and cost. Many gene therapies carry extraordinary price tags, raising hard questions about how health systems pay for one-time treatments with lasting benefits. Resolving those questions, experts say, will determine whether the scientific breakthroughs reach everyone who could benefit.
More in Health & Medicine
FDA Licenses the First Freeze-Dried Plasma Product in the U.S.
Regulators approved the country's first freeze-dried plasma, a shelf-stable blood product that could ease transfusion logistics in trauma care and emergency settings.
Health Officials Investigate a Multistate Cyclospora Outbreak Tied to Produce
Federal investigators are working to pin down the source of a cyclosporiasis outbreak reported across several states, a recurring summertime challenge linked to fresh produce.
FDA Advisory Panel Backs Compounding of Two Peptides, Drawing Expert Caution
A federal advisory committee recommended allowing two peptides to be compounded, but specialists warned the move could be misread as a sign the compounds have been fully vetted.